230 related articles for article (PubMed ID: 28983805)
1. Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.
Yan X; Clemens PL; Puchalski T; Lonial S; Lokhorst H; Voorhees PM; Usmani S; Richardson PG; Plesner T; Liu K; Orlowski RZ; Losic N; Jansson R; Ahmadi T; Lantz K; Ruixo JJP; Zhou H; Xu XS
Clin Pharmacokinet; 2018 Apr; 57(4):529-538. PubMed ID: 28983805
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
Usmani SZ; Nahi H; Plesner T; Weiss BM; Bahlis NJ; Belch A; Voorhees PM; Laubach JP; van de Donk NWCJ; Ahmadi T; Uhlar CM; Wang J; Feng H; Qi M; Richardson PG; Lonial S
Lancet Haematol; 2020 Jun; 7(6):e447-e455. PubMed ID: 32470437
[TBL] [Abstract][Full Text] [Related]
3. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
[TBL] [Abstract][Full Text] [Related]
4. Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients.
Fau JB; El-Cheikh R; Brillac C; Koiwai K; Mace N; Campana F; Semiond D; Nguyen L
CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):649-658. PubMed ID: 33021075
[TBL] [Abstract][Full Text] [Related]
5. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Chari A; Lonial S; Mark TM; Krishnan AY; Stockerl-Goldstein KE; Usmani SZ; Londhe A; Etheredge D; Fleming S; Liu B; Ukropec J; Lin TS; Jagannath S; Nooka AK
Cancer; 2018 Nov; 124(22):4342-4349. PubMed ID: 30395359
[TBL] [Abstract][Full Text] [Related]
6. Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma.
Xu XS; Yan X; Puchalski T; Lonial S; Lokhorst HM; Voorhees PM; Plesner T; Liu K; Khan I; Jansson R; Ahmadi T; Ruixo JP; Zhou H; Clemens PL
Clin Pharmacol Ther; 2017 Jun; 101(6):721-724. PubMed ID: 27859027
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.
Iida S; Ishikawa T; Min CK; Kim K; Yeh SP; Usmani SZ; Mateos MV; Nahi H; Heuck C; Qin X; Parasrampuria DA; Gries KS; Qi M; Bahlis N; Ito S
Ann Hematol; 2021 Apr; 100(4):1065-1077. PubMed ID: 33599794
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab provides a survival benefit in relapsed and refractory Multiple Myeloma, independent of baseline clinical characteristics: A meta-analysis.
Cao C; Zhou X; Ma Q
Pharmacol Res Perspect; 2021 Aug; 9(4):e00797. PubMed ID: 34128350
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Sherbenou DW; Mark TM; Forsberg P
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
[TBL] [Abstract][Full Text] [Related]
10. Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab.
Kim K; Phelps MA
Clin Pharmacokinet; 2023 Jun; 62(6):789-806. PubMed ID: 37129750
[TBL] [Abstract][Full Text] [Related]
11. Daratumumab in multiple myeloma.
Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan A; Vescio RA; Mateos MV; Mazumder A; Orlowski RZ; Sutherland HJ; Bladé J; Scott EC; Oriol A; Berdeja J; Gharibo M; Stevens DA; LeBlanc R; Sebag M; Callander N; Jakubowiak A; White D; de la Rubia J; Richardson PG; Lisby S; Feng H; Uhlar CM; Khan I; Ahmadi T; Voorhees PM
Lancet; 2016 Apr; 387(10027):1551-1560. PubMed ID: 26778538
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.
Clemens PL; Yan X; Lokhorst HM; Lonial S; Losic N; Khan I; Jansson R; Ahmadi T; Lantz K; Zhou H; Puchalski T; Xu XS
Clin Pharmacokinet; 2017 Aug; 56(8):915-924. PubMed ID: 27896689
[TBL] [Abstract][Full Text] [Related]
14. Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.
Van Sanden S; Ito T; Diels J; Vogel M; Belch A; Oriol A
Oncologist; 2018 Mar; 23(3):279-287. PubMed ID: 29192016
[TBL] [Abstract][Full Text] [Related]
15. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
Jullien M; Trudel S; Tessoulin B; Mahé B; Dubruille V; Blin N; Gastinne T; Bonnet A; Lok A; Lebourgeois A; Peterlin P; Garnier A; Chevalier P; Guillaume T; Thomaré P; Le Gouill S; Moreau P; Touzeau C
Ann Hematol; 2019 Jun; 98(6):1435-1440. PubMed ID: 30874850
[TBL] [Abstract][Full Text] [Related]
16. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
Lokhorst HM; Plesner T; Laubach JP; Nahi H; Gimsing P; Hansson M; Minnema MC; Lassen U; Krejcik J; Palumbo A; van de Donk NW; Ahmadi T; Khan I; Uhlar CM; Wang J; Sasser AK; Losic N; Lisby S; Basse L; Brun N; Richardson PG
N Engl J Med; 2015 Sep; 373(13):1207-19. PubMed ID: 26308596
[TBL] [Abstract][Full Text] [Related]
17. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.
Usmani SZ; Diels J; Ito T; Mehra M; Khan I; Lam A
Am J Hematol; 2017 Aug; 92(8):E146-E152. PubMed ID: 28474745
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma.
Paul B; Atrash S; Bhutani M; Voorhees P; Hamadeh I; Usmani SZ
Expert Rev Hematol; 2020 Aug; 13(8):795-802. PubMed ID: 32659139
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study.
Iida S; Suzuki K; Kusumoto S; Ri M; Tsukada N; Abe Y; Aoki M; Inagaki M
Int J Hematol; 2017 Oct; 106(4):541-551. PubMed ID: 28643017
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab plus bortezomib and dexamethasone
Spencer A; Lentzsch S; Weisel K; Avet-Loiseau H; Mark TM; Spicka I; Masszi T; Lauri B; Levin MD; Bosi A; Hungria V; Cavo M; Lee JJ; Nooka AK; Quach H; Lee C; Barreto W; Corradini P; Min CK; Scott EC; Chanan-Khan AA; Horvath N; Capra M; Beksac M; Ovilla R; Jo JC; Shin HJ; Sonneveld P; Soong D; Casneuf T; Chiu C; Amin H; Qi M; Thiyagarajah P; Sasser AK; Schecter JM; Mateos MV
Haematologica; 2018 Dec; 103(12):2079-2087. PubMed ID: 30237264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
